News >

Expert Highlights Biological Advancements in Bladder Cancer Field

Angelica Welch
Published: Tuesday, Oct 03, 2017

Brant Inman, MD

Brant Inman, MD
The 5 FDA approvals of checkpoint inhibitors in the bladder cancer paradigm over a 2-year period are largely due to the improved understanding of the disease on a biological level, according to Brant Inman, MD.

on Genitourinary Cancers.

OncLive: Can you please provide an overview of your discussion on bladder cancer?

Inman: I spoke about 3 things: the biology of bladder cancer and how it has changed the way we are managing patients, the standard of care right now for managing muscle-invasive bladder cancer, and the role of chemotherapy with or without surgery, as well as the types of chemotherapy regimens we should be using.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication